Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. reports developments as a global animal health company serving veterinarians, livestock producers and pet owners. Its updates center on medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for companion animals and livestock, organized commercially through U.S. and International segments.
Recurring news includes quarterly results and guidance, dividend declarations, investor conference presentations, pipeline and product-regulatory updates, and portfolio activity tied to animal health innovation. Company materials also describe R&D work across areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity, as well as approved long-acting osteoarthritis pain products Lenivia and Portela.
Zoetis (NYSE: ZTS) priced $1.75 billion of 0.25% convertible senior notes due 2029, with a $250 million option for additional notes, and expects the offering to close on December 18, 2025. Net proceeds are estimated at approximately $1,723.2 million (or $1,969.6 million if option exercised).
Zoetis intends to use proceeds to fund capped calls (~$163.3 million), purchase ~2.1 million shares for ~$250.3 million now, and repurchase approximately $1.6 billion of common stock (or ~$1.8 billion if option exercised) by Q1 2026.
Key terms: 0.25% coupon, maturity June 15, 2029, initial conversion price ~$148.20 (22.5% premium), cap price for capped calls $211.7150 (75% premium).
Zoetis (NYSE: ZTS) intends to offer $1.75 billion aggregate principal amount of convertible senior notes due June 15, 2029, with an initial purchaser option for an additional $250 million. Net proceeds are expected to fund (i) capped call transactions, (ii) privately negotiated repurchases of common stock and (iii) additional share repurchases to be completed by no later than the first quarter of 2026. Repurchases will be made under the company’s existing $6 billion repurchase program. Capped calls are expected to limit dilution, while option counterparties may hedge by buying or trading Zoetis stock, which could affect market price.
Zoetis (NYSE:ZTS) declared a $0.53 per share dividend for Q1 2026, a 6% increase from the quarterly rate paid in 2025. The dividend is payable on March 3, 2026 to shareholders of record at the close of business on January 20, 2026.
Zoetis (NYSE:ZTS) announced Health Canada approval of Portela (relfovetmab injection) on December 5, 2025, for alleviating pain associated with osteoarthritis (OA) in cats.
Portela is designed to provide three months of OA pain relief from a single injection, targets nerve growth factor (NGF), showed effectiveness in a nine-month field trial in Europe, and was well tolerated including in cats with IRIS stage 1–3 kidney disease. Portela is already approved in the EU and Zoetis anticipates commercial availability in Canada and the EU in 2026.
Zoetis (NYSE: ZTS) hosted an Innovation Webcast on December 2, 2025 to outline its R&D strategy, diversified pipeline and growth catalysts. The company highlighted a 12-candidate pipeline with blockbuster potential, expansion into chronic kidney disease, oncology and cardiology, and a long-term animal health market projected to approach $90 billion by 2035. Zoetis said those therapeutic frontiers plus lifecycle and geographic expansion represent roughly $5 billion in addressable opportunity and underpin its aim to drive sustained revenue growth, profitability and ROIC.
Management participating included CEO Kristin Peck and R&D and finance leaders; the webcast and slides are available on the company investor website with a replay posted after the event.
Zoetis (NYSE: ZTS) announced on November 26, 2025 that the European Commission granted marketing authorization for Lenivia (izenivetmab) to reduce pain associated with osteoarthritis (OA) in dogs.
Lenivia is described as a long‑acting monoclonal antibody targeting nerve growth factor (NGF) that can reduce OA pain for three months with one injection. A nine‑month field study reported a safety profile with dogs showing increased mobility and decreased pain after one injection. Lenivia will join Librela (bedinvetmab) in Zoetis’ portfolio of OA pain therapies for dogs.
Zoetis (NYSE:ZTS) will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET.
Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to analyst questions. Investors can listen via a live audio webcast at http://investor.zoetis.com/events-presentations, with a replay posted on the Zoetis investor website after the event.
Zoetis (NYSE: ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025 with CEO Kristin Peck, CFO Wetteny Joseph, EVP & President R&D Rob Polzer, and SVP Global Therapeutics Kevin Esch.
The webcast will include pipeline updates, the company’s strategic approach to unmet animal health needs, R&D capabilities, long‑term growth potential, and live Q&A. The release notes that Dr. Esch will succeed Dr. Polzer, effective January 1, 2026.
Investors can access the live webcast and slides via the company investor website, pre‑registration opens today, and a replay will be available after the event.
Summary not available.
Zoetis (NYSE: ZTS) announced that Rob Polzer, EVP and President, Research & Development, will retire at the end of 2025 and leave the company on February 28, 2026, remaining as a scientific advisor through 2026. Zoetis named Kevin Esch, DVM, MPH, PhD, Dipl. ACVP, currently SVP of Global Therapeutics, to succeed Polzer effective January 1, 2026. Esch will join the executive team and report to CEO Kristin Peck.
The release highlights Zoetis’ R&D scale: 17 blockbuster products, more than 2,000 new products and lifecycle innovations in the last 12 years, and an expectation of a significant approval in a major market each year for the next several years. Zoetis will host an Innovation Webcast on December 2, 2025 at 8:30 a.m. ET.